Welcome to the newly launched CancerTYPE ID® blog!

Thank you for joining us! We’ve launched this blog for healthcare professionals interested in advances in the molecular diagnosis for metastatic cancers. This blog will discuss results from CancerTYPE ID, a molecular classifier that provides a diagnosis of tumor type based on cell lineage. With a single diagnosis, additional information, such as guideline recommended biomarkers, may inform treatment decisions.

“The blog will cover topics related to new information on CancerTYPE ID molecular classification of metastatic cancers that impacts clinical decisions in practice today.”

In addition to discussing ways in which molecular classification may improve clinical decision-making for metastatic cancers, this blog will also provide information on the latest advancements in diagnosing metastatic cancers from peer-reviewed journals and late-breaking data from scientific meetings.

Our hope is that you find the information presented here to be useful for your clinical practice. We encourage you to comment and be part of the dialogue, starting with: What are some topics of interest to you? Do you have specific questions about how molecular classification of metastatic cancers can have an impact on your clinical practice?
Share a diagnostic dilemma that you have faced recently.

Again, welcome! We look forward to sharing this information with you!


Want to learn more about CancerTYPE ID? Order a test? Start here.

to our blog for updates.

Coming soon to the blog: “Resolution of Diagnostic Dilemmas in Oncology”


CancerTYPE ID Intended Use and Limitations
CancerTYPE ID is indicated for use in tumor specimens from patients diagnosed with malignant disease and is intended to aid in the classification of the tissue of origin and tumor subtype in conjunction with standard clinical and pathological assessment by a qualified physician. CancerTYPE ID is not intended to predict patient survival benefit, treatment efficacy or to distinguish between benign versus malignant lesions. Tumor types not included in the CancerTYPE ID reference database may exhibit RNA expression patterns that are similar to RNA expression patterns within the reference database. This test was developed and performance characteristics have been determined by Biotheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory Improvement Amendments of 1988 as qualified to perform high-complexity clinical laboratory testing.